2nd Quarter - Report
W STRATEGIES, LLC for BIOGEN
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 5651: Food and Drug Administration Reform Act of 2012, S. 3187: Food and Drug Administration Safety and Innovation Act of 2012, particularly provisions relating to accelerated approval of drugs. Advocated for reforms of Risk Evaluation and Mitigation Strategies in FDA bills.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.